MCL1 and neoplasm: In conclusion, in this study we demonstrate that inhibition of two master regulators of cell survival, MCL-1 and BCL-2 with clinical stage drugs, voruciclib and venetoclax respectively, can achieve synergistic anti-tumor efficacy in a subset of ABC DLBCL models.